Pharma Meets AI: The Rising Collaboration Between Drugmakers and OpenAI-Driven Technologies

Introduction

For years, pharmaceutical companies have invested in analytics, automation and machine learning. What is changing now is the scale and usability of generative AI. OpenAI-driven technologies are shifting the industry from isolated digital pilots to a broader operating model in which research, clinical development, regulatory work, manufacturing support and commercial communication can all be augmented by intelligent systems. This is no longer a side initiative owned only by innovation teams; it is increasingly becoming a strategic capability discussed at board level. The market momentum behind this shift is already visible. TechSci Research estimates that the Global Generative AI in Pharmaceutical Market will grow from USD 4.20 billion in 2025 to USD 19.13 billion by 2031, at a CAGR of 28.75%

This momentum is not limited to pharma-specific applications alone. TechSci Research also projects that the Global AI in Healthcare Market will expand from USD 36.02 billion in 2025 to USD 250.08 billion by 2031, at a CAGR of 38.12%. That wider healthcare expansion matters, because pharmaceutical companies do not operate in isolation; they are part of an interconnected healthcare ecosystem involving providers, payers, regulators, researchers and patients. As AI capabilities mature across that system, pharma has a clear incentive to adopt them earlier and more systematically.

At the same time, the economic case for AI is becoming harder to ignore. The industry forecasts suggest machine learning applied to target discovery, molecule design and clinical-trial planning could halve early-stage development timelines and costs within the next three to five years. For an industry defined by high attrition rates, expensive trials and long development cycles, even partial gains on that scale would be transformative.

What OpenAI-Driven Technologies Actually Mean for Pharma

When executives talk about OpenAI-driven technologies in pharma, they are not referring only to chatbots that summarise research papers. The opportunity is much broader. OpenAI positions its life sciences offering around secure enterprise deployment, API-based custom applications, intelligent agents, scientific reasoning models and systems that can connect to proprietary internal data. According to OpenAI, life sciences organisations can use these tools to accelerate insights and automate workflows across R&D, clinical, regulatory and manufacturing functions.

This is a critical distinction. Pharma creates value through a chain of highly specialised decisions. In discovery, teams need faster literature synthesis, stronger biological hypothesis generation and better target prioritisation. In preclinical work, they need support with data interpretation, mechanism comparison and experiment planning. In clinical development, they need help with protocol refinement, dose selection, patient stratification and evidence review. In regulatory and medical affairs, they need high-quality drafting, source traceability and rapid interrogation of internal knowledge. In manufacturing and commercial operations, they need document support, workflow assistance and faster access to validated information. OpenAI-driven technologies are attractive because they can support all of these functions while remaining adaptable to highly regulated environments.

How Pharma Companies Will Be Leveraging AI

1. Drug Discovery and Target Identification

Drug discovery remains one of the most visible areas for AI deployment. Scientists must process enormous volumes of literature, pathway data, omics datasets and prior experiment results before deciding which targets deserve investment. OpenAI’s life sciences approach is designed to help researchers move faster through evidence synthesis, hypothesis generation and experimental planning. By shortening the time between question and insight, AI can help companies identify better targets earlier and reduce wasted effort on weaker hypotheses

OpenAI’s scientific model, GPT-Rosalind, makes this especially relevant for pharma. The company says the model is built to support research across biology, drug discovery and translational medicine, and can help with chemistry, protein engineering, genomics, literature review, sequence-to-function interpretation and data analysis. OpenAI also notes that the accompanying life sciences research plugin can connect users to more than 50 public multi-omics databases, literature sources and biology tools. This suggests that future AI value in pharma will come not just from text generation, but from multi-step scientific reasoning across tools and data environments.

2. Preclinical and Translational Research

Preclinical teams operate at the boundary between discovery and clinical application. They need to evaluate compounds, compare biological signals, interpret early findings and decide what deserves further investment. AI can help them test more ideas, structure evidence more efficiently and identify patterns that may otherwise remain buried in fragmented datasets. In practice, this means improved candidate prioritisation, better biomarker exploration and more informed experimental follow-up.

This matters commercially because early mistakes in development are expensive. If AI helps teams eliminate weaker candidates sooner and strengthen the evidence base behind promising ones, portfolio productivity can improve materially. That is why the AI discussion in pharma is increasingly moving from “can it automate tasks?” to “can it improve decision quality?” The latter is where strategic value is likely to be concentrated.

3. Clinical Development and Trial Design

Clinical development is another high-value use case. AI can support protocol analysis, dose evaluation, evidence retrieval, operational planning and data summarisation. In an environment where delays are expensive and trial complexity is increasing; these capabilities can improve speed without necessarily compromising rigour. Properly governed, AI can reduce friction in the preparation and analysis layers that surround major development decisions.

This is also where the broader economics become compelling. Development programs fail not only because the science is wrong, but because the operational execution is slow, fragmented or inconsistent. AI can help teams compare more evidence, create more consistent documentation and shorten repetitive review cycles. Over time, that may improve not just speed, but the overall reliability of development processes.

4. Regulatory, Medical Affairs and Enterprise Knowledge

A large share of pharmaceutical complexity lies outside the lab. Teams across regulatory, legal, procurement, quality and medical affairs spend significant time searching for internal knowledge, summarising documents, checking precedents and converting technical information into audience-specific communications. OpenAI’s life sciences platform explicitly addresses this by allowing teams to query trial data, internal knowledge and literature in secure enterprise environments, and by enabling organisations to build custom systems around those workflows.

This may become one of the most immediate areas of value creation because the gains are highly scalable. Even if AI does not invent a molecule on its own, it can materially reduce the friction surrounding how humans work with documentation, evidence and institutional knowledge. In pharma, where every decision is linked to traceability and review, that kind of operating leverage is strategically important.

5. Manufacturing, Commercial and Corporate Functions

The strongest pharma AI stories are no longer confined to scientists. AI is moving into manufacturing support, legal review, policy assistance, investor communication and other enterprise functions. This matters because pharmaceutical performance depends on far more than research productivity alone. If AI accelerates knowledge retrieval, improves consistency of communication and supports decision-making across business operations, it can raise the execution speed of the whole company.

Moderna: A Leading Example of Enterprise-Scale Adoption

One of the clearest examples of OpenAI-driven transformation in pharma comes from Moderna. In April 2024, Moderna and OpenAI announced an ongoing collaboration aimed at advancing mRNA medicine through enterprise use of generative AI. According to Moderna, the company first launched its own internal instance of ChatGPT, called mChat, built on OpenAI’s API. That system achieved more than 80% internal adoption, creating the foundation for wider AI deployment across the organisation.

The scale of adoption is especially notable. OpenAI’s Moderna case study says that within two months of adopting ChatGPT Enterprise, Moderna had 750 GPTs across the company, while 40% of weekly active users created GPTs, and each user averaged 120 ChatGPT Enterprise conversations per week. Moderna also stated that it was using its platform to bring up to 15 new products to market in the next five years. Those numbers matter because they show AI becoming embedded in daily enterprise activity rather than remaining a pilot project.

More importantly, Moderna has described use cases across multiple business functions. The company says GPTs are used across legal, research, manufacturing and commercial teams. One example is Dose ID, a GPT designed to support the evaluation of optimal vaccine dose selection by analysing clinical data, applying dose-selection criteria, referencing sources and generating charts. This is a strong example of how AI can augment specialist work without replacing human judgment.

Moderna’s leadership has also framed AI as an enterprise redesign tool. CEO Stéphane Bancel said the company is looking at every business process, from legal to research to manufacturing to commercial, and considering how to redesign those processes with AI. That statement is revealing because it signals a strategic posture: AI is not being treated as a feature, but as a new operating layer for the company.

Sanofi: Building AI Across the Drug Development Lifecycle

Sanofi has taken a more platform-oriented approach. In May 2024, Sanofi, Formation Bio and OpenAI announced a collaboration to build AI-powered software intended to accelerate drug development and bring medicines to patients more efficiently. The three parties said they would combine data, software and tuned models to create custom, purpose-built solutions across the drug development lifecycle. Sanofi described the initiative as a first-of-its-kind collaboration in pharma and life sciences.

Sanofi CEO Paul Hudson’s statement is especially useful in understanding strategic intent. He said the collaboration is another major step in Sanofi’s journey to becoming a pharmaceutical company “substantially powered by AI.” That choice of language matters. It suggests Sanofi sees AI not as a productivity accessory, but as a core capability for development execution, model customisation and enterprise scaling.

Eli Lilly: Using AI for Novel Antimicrobials

Eli Lilly’s collaboration with OpenAI highlights another dimension of the opportunity: targeted scientific use in high-need disease areas. In June 2024, Lilly announced a collaboration with OpenAI that would allow the company to use generative AI to invent novel antimicrobials for drug-resistant pathogens. That is significant not just because of the science involved, but because antimicrobial resistance is a major global health challenge where innovation has often lagged.

Lilly also linked the collaboration to its earlier commitment to antimicrobial resistance. The release noted that in 2020 the company’s social impact venture portfolio committed USD 100 million to the AMR Action Fund, which aims to help provide two to four new antibiotics by 2030. That context shows how AI can fit into a broader strategic and public health agenda rather than sitting as an isolated technical initiative.

The Market Signals Behind the Shift

The move toward AI-enabled pharma is supported by more than case studies. It is also supported by market demand signals. TechSci Research estimates that the Global AI in Life Science Market will rise from USD 14.21 billion in 2025 to USD 33.61 billion by 2031, at a CAGR of 15.43%. That forecast reinforces the idea that life sciences organisations are formalising AI investment rather than treating it as a temporary innovation trend.

Language-based AI is also emerging as an important commercial layer. TechSci Research projects that the Global Conversational AI in Healthcare Market will grow from USD 13.89 billion in 2025 to USD 50.27 billion by 2031, at a CAGR of 23.91%. For pharma companies, that has clear relevance for medical information, internal support systems, field-force enablement, patient services and knowledge retrieval.

Together, these figures suggest that the AI opportunity is no longer theoretical. It is already spreading across healthcare and life sciences infrastructure, and pharma is increasingly positioning itself to capture value from that transition.

What Will Separate the Winners from the Followers

Not every pharmaceutical company will benefit equally. The organisations most likely to succeed will be those that combine AI capability with strong governance, high-quality data foundations and clearly defined use cases. In pharma, hallucinated content, weak traceability or uncontrolled data handling are not minor problems; they are material risks. That is why enterprise deployment, access controls and human oversight are central to the OpenAI life sciences model.

The winners will also avoid thinking about AI only in terms of headcount reduction. The more strategic lens is throughput, quality and optionality. If scientists can test more hypotheses, if clinical teams can compare more evidence, and if regulatory or legal teams can retrieve and structure information faster, the result is a better allocation of expert time. The strongest pharma AI stories are therefore about augmentation, not replacement. Moderna, Sanofi and Lilly all illustrate this point in different ways.

Conclusion: AI Is Becoming Pharma’s New Operating Layer

The most realistic near-term outcome is not that AI will independently discover and commercialise drugs. Rather, AI will increasingly function as a force multiplier across discovery, development and enterprise execution. It will help drugmakers ask better questions, process more evidence, make faster operational decisions and turn complexity into usable insight.